Loading…
Relation of AURKB over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines
New therapeutic drug for breast cancer (BRCA), especially triple negative BRCA (TNBC), is urgently needed. Even though 2-(4-morpholinoanilino)-6-cyclohexylaminopurine (reversine) is an aurora kinase inhibitor, it also inhibits some cancer cells and human BRCA cells. However, the potential roles of r...
Saved in:
Published in: | Cancer cell international 2019-06, Vol.19 (1), p.166-166, Article 166 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c594t-71abc2c2162f5392e9705ddf5fd0efc26530798aafcd2a8ff1e634cd13d66d53 |
---|---|
cites | cdi_FETCH-LOGICAL-c594t-71abc2c2162f5392e9705ddf5fd0efc26530798aafcd2a8ff1e634cd13d66d53 |
container_end_page | 166 |
container_issue | 1 |
container_start_page | 166 |
container_title | Cancer cell international |
container_volume | 19 |
creator | Huang, Di Huang, Yu Huang, Zisheng Weng, Jiefeng Zhang, Shuai Gu, Weili |
description | New therapeutic drug for breast cancer (BRCA), especially triple negative BRCA (TNBC), is urgently needed. Even though 2-(4-morpholinoanilino)-6-cyclohexylaminopurine (reversine) is an aurora kinase inhibitor, it also inhibits some cancer cells and human BRCA cells. However, the potential roles of reversine as a novel therapeutic agent for the treatment of BRCA remains unknown and must be further investigation. Thus, the relationship of reversine to aurora kinase in BCRA has not been reported. The relationship between AURKB and survival rate in BRCA has never been reported. Herein, we tested the roles of reversine on different BRCA cell line subtypes. We also investigated the relationship between AURKB and survival rate in BRCA as well as reversine to Aurora kinase expression in BCRA cell lines, including TNBC subtype, 4T1, MDA-MB-231, and luminal subtype MCF-7.
Cell viability and apoptosis were detected using Cell Counting Kit-8 and flow cytometry analysis, respectively. Apoptotic and tumor-related proteins were tested using Western blot analysis. Important microRNAs that regulate BRCA were analyzed using RT-PCR. UALCAN public databases were used to analyze the targeted gene profiles, and the PROGgeneV2 database was used to study the prognostic implications of genes.
Reversine inhibits cell proliferation and induces cell apoptosis by modulating caspase-3 and bax/bcl-2 among the three cell lines. Data from the UALCAN public database show that BRCA tissues expressed high gene levels of
, and
compared with the normal tissue. Among the over-expressed genes in BRCA,
ranks 9th in TNBC, 49th in luminal subtype, and 48th in HER2 subtype. High
level in BRCA is highly related to the low survival rate in patients displayed in 18 databases searched via PROGgeneV2. The protein levels of aurora B kinase (Aurora B), which is encoded by
gene, are highly suppressed by reversine in the three cell lines. The tumor-related proteins TGF-β1, TIMP1, and MMP9 are partially suppressed by reversine but with different sensitivity in the three cell lines. The reversine-affected microRNAs, such as miR129-5p, miR-199a-3p, and miR-3960, in MDA-MB-231 cell line might be the research targets in TNBC regulation.
In BRCA, the level of
are over-expressed and is related to low survival rate. Reversine contributes to anti-growth effect in BRCA cell lines, especially for TNBC, by modulating the aurora B. However, the invasiveness, metastasis, and anti-tumor effects of reversine in vivo and in |
doi_str_mv | 10.1186/s12935-019-0885-z |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_ccad0b4c4bf84f3c8820da912829ccfc</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_ccad0b4c4bf84f3c8820da912829ccfc</doaj_id><sourcerecordid>2243407000</sourcerecordid><originalsourceid>FETCH-LOGICAL-c594t-71abc2c2162f5392e9705ddf5fd0efc26530798aafcd2a8ff1e634cd13d66d53</originalsourceid><addsrcrecordid>eNpdkk9v1DAQxSMEoqXwAbggS1x6Cfhv4lyQdlfQVlRCWpWzNbHHJUvWXuxkgR755CTdUrWcPPK899PM6BXFa0bfMaar95nxRqiSsqakWqvy5klxzGStSq6r-umD-qh4kfOGUlbrij4vjgTjUiolj4s_a-xh6GIg0ZPF1_XnJYl7TCX-2iXMeW4MkfTxJ8lj2nd76EmCAUkXyHK1XhAIjiScHLkLWG6jGyccOgJjignIknzvAuRbfZsQ8kAsBIuJWOx70k-m_LJ45qHP-OruPSmuPn28Wp2Xl1_OLlaLy9KqRg5lzaC13HJWca9Ew7GpqXLOK-8oessrJWjdaABvHQftPcNKSOuYcFXllDgpLg5YF2FjdqnbQvptInTm9iOmawNp6GyPxlpwtJVWtl5LL6zWnDpoGNe8sdbbifXhwNqN7RadxTAk6B9BH3dC981cx72plOZKzsOc3gFS_DFiHsy2y_NJIGAcs-FcalGrupmlb_-TbuKYwnSpWSUkrSmlk4odVDbFnBP6-2EYNXNYzCEsZgqLmcNibibPm4db3Dv-pUP8BRO0vR8</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2243407000</pqid></control><display><type>article</type><title>Relation of AURKB over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines</title><source>PubMed (Medline)</source><source>Publicly Available Content (ProQuest)</source><creator>Huang, Di ; Huang, Yu ; Huang, Zisheng ; Weng, Jiefeng ; Zhang, Shuai ; Gu, Weili</creator><creatorcontrib>Huang, Di ; Huang, Yu ; Huang, Zisheng ; Weng, Jiefeng ; Zhang, Shuai ; Gu, Weili</creatorcontrib><description>New therapeutic drug for breast cancer (BRCA), especially triple negative BRCA (TNBC), is urgently needed. Even though 2-(4-morpholinoanilino)-6-cyclohexylaminopurine (reversine) is an aurora kinase inhibitor, it also inhibits some cancer cells and human BRCA cells. However, the potential roles of reversine as a novel therapeutic agent for the treatment of BRCA remains unknown and must be further investigation. Thus, the relationship of reversine to aurora kinase in BCRA has not been reported. The relationship between AURKB and survival rate in BRCA has never been reported. Herein, we tested the roles of reversine on different BRCA cell line subtypes. We also investigated the relationship between AURKB and survival rate in BRCA as well as reversine to Aurora kinase expression in BCRA cell lines, including TNBC subtype, 4T1, MDA-MB-231, and luminal subtype MCF-7.
Cell viability and apoptosis were detected using Cell Counting Kit-8 and flow cytometry analysis, respectively. Apoptotic and tumor-related proteins were tested using Western blot analysis. Important microRNAs that regulate BRCA were analyzed using RT-PCR. UALCAN public databases were used to analyze the targeted gene profiles, and the PROGgeneV2 database was used to study the prognostic implications of genes.
Reversine inhibits cell proliferation and induces cell apoptosis by modulating caspase-3 and bax/bcl-2 among the three cell lines. Data from the UALCAN public database show that BRCA tissues expressed high gene levels of
, and
compared with the normal tissue. Among the over-expressed genes in BRCA,
ranks 9th in TNBC, 49th in luminal subtype, and 48th in HER2 subtype. High
level in BRCA is highly related to the low survival rate in patients displayed in 18 databases searched via PROGgeneV2. The protein levels of aurora B kinase (Aurora B), which is encoded by
gene, are highly suppressed by reversine in the three cell lines. The tumor-related proteins TGF-β1, TIMP1, and MMP9 are partially suppressed by reversine but with different sensitivity in the three cell lines. The reversine-affected microRNAs, such as miR129-5p, miR-199a-3p, and miR-3960, in MDA-MB-231 cell line might be the research targets in TNBC regulation.
In BRCA, the level of
are over-expressed and is related to low survival rate. Reversine contributes to anti-growth effect in BRCA cell lines, especially for TNBC, by modulating the aurora B. However, the invasiveness, metastasis, and anti-tumor effects of reversine in vivo and in vitro must be further investigated.</description><identifier>ISSN: 1475-2867</identifier><identifier>EISSN: 1475-2867</identifier><identifier>DOI: 10.1186/s12935-019-0885-z</identifier><identifier>PMID: 31244554</identifier><language>eng</language><publisher>England: BioMed Central</publisher><subject>Apoptosis ; AURKB ; Aurora B ; Aurora B protein ; Aurora kinase ; BAX protein ; Bcl-2 protein ; BRCA ; Breast cancer ; Cancer therapies ; Caspase ; Caspase-3 ; Cell cycle ; Cell lines ; Cell proliferation ; Cell viability ; Chemical compounds ; Enzyme inhibitors ; ErbB-2 protein ; Fibroblasts ; Flow cytometry ; Gelatinase B ; Genes ; Invasiveness ; Kinases ; Medical prognosis ; Metastases ; MicroRNAs ; miRNA ; Overexpression ; Polymerase chain reaction ; Polyploidy ; Primary Research ; Proteins ; Reversine ; Stem cells ; Survival ; Tissue inhibitor of metalloproteinase 1 ; Transforming growth factor-b1 ; Triple-negative breast cancer cells ; Tumor cell lines ; Viability</subject><ispartof>Cancer cell international, 2019-06, Vol.19 (1), p.166-166, Article 166</ispartof><rights>2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c594t-71abc2c2162f5392e9705ddf5fd0efc26530798aafcd2a8ff1e634cd13d66d53</citedby><cites>FETCH-LOGICAL-c594t-71abc2c2162f5392e9705ddf5fd0efc26530798aafcd2a8ff1e634cd13d66d53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582545/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2243407000?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31244554$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Di</creatorcontrib><creatorcontrib>Huang, Yu</creatorcontrib><creatorcontrib>Huang, Zisheng</creatorcontrib><creatorcontrib>Weng, Jiefeng</creatorcontrib><creatorcontrib>Zhang, Shuai</creatorcontrib><creatorcontrib>Gu, Weili</creatorcontrib><title>Relation of AURKB over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines</title><title>Cancer cell international</title><addtitle>Cancer Cell Int</addtitle><description>New therapeutic drug for breast cancer (BRCA), especially triple negative BRCA (TNBC), is urgently needed. Even though 2-(4-morpholinoanilino)-6-cyclohexylaminopurine (reversine) is an aurora kinase inhibitor, it also inhibits some cancer cells and human BRCA cells. However, the potential roles of reversine as a novel therapeutic agent for the treatment of BRCA remains unknown and must be further investigation. Thus, the relationship of reversine to aurora kinase in BCRA has not been reported. The relationship between AURKB and survival rate in BRCA has never been reported. Herein, we tested the roles of reversine on different BRCA cell line subtypes. We also investigated the relationship between AURKB and survival rate in BRCA as well as reversine to Aurora kinase expression in BCRA cell lines, including TNBC subtype, 4T1, MDA-MB-231, and luminal subtype MCF-7.
Cell viability and apoptosis were detected using Cell Counting Kit-8 and flow cytometry analysis, respectively. Apoptotic and tumor-related proteins were tested using Western blot analysis. Important microRNAs that regulate BRCA were analyzed using RT-PCR. UALCAN public databases were used to analyze the targeted gene profiles, and the PROGgeneV2 database was used to study the prognostic implications of genes.
Reversine inhibits cell proliferation and induces cell apoptosis by modulating caspase-3 and bax/bcl-2 among the three cell lines. Data from the UALCAN public database show that BRCA tissues expressed high gene levels of
, and
compared with the normal tissue. Among the over-expressed genes in BRCA,
ranks 9th in TNBC, 49th in luminal subtype, and 48th in HER2 subtype. High
level in BRCA is highly related to the low survival rate in patients displayed in 18 databases searched via PROGgeneV2. The protein levels of aurora B kinase (Aurora B), which is encoded by
gene, are highly suppressed by reversine in the three cell lines. The tumor-related proteins TGF-β1, TIMP1, and MMP9 are partially suppressed by reversine but with different sensitivity in the three cell lines. The reversine-affected microRNAs, such as miR129-5p, miR-199a-3p, and miR-3960, in MDA-MB-231 cell line might be the research targets in TNBC regulation.
In BRCA, the level of
are over-expressed and is related to low survival rate. Reversine contributes to anti-growth effect in BRCA cell lines, especially for TNBC, by modulating the aurora B. However, the invasiveness, metastasis, and anti-tumor effects of reversine in vivo and in vitro must be further investigated.</description><subject>Apoptosis</subject><subject>AURKB</subject><subject>Aurora B</subject><subject>Aurora B protein</subject><subject>Aurora kinase</subject><subject>BAX protein</subject><subject>Bcl-2 protein</subject><subject>BRCA</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Caspase</subject><subject>Caspase-3</subject><subject>Cell cycle</subject><subject>Cell lines</subject><subject>Cell proliferation</subject><subject>Cell viability</subject><subject>Chemical compounds</subject><subject>Enzyme inhibitors</subject><subject>ErbB-2 protein</subject><subject>Fibroblasts</subject><subject>Flow cytometry</subject><subject>Gelatinase B</subject><subject>Genes</subject><subject>Invasiveness</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>MicroRNAs</subject><subject>miRNA</subject><subject>Overexpression</subject><subject>Polymerase chain reaction</subject><subject>Polyploidy</subject><subject>Primary Research</subject><subject>Proteins</subject><subject>Reversine</subject><subject>Stem cells</subject><subject>Survival</subject><subject>Tissue inhibitor of metalloproteinase 1</subject><subject>Transforming growth factor-b1</subject><subject>Triple-negative breast cancer cells</subject><subject>Tumor cell lines</subject><subject>Viability</subject><issn>1475-2867</issn><issn>1475-2867</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkk9v1DAQxSMEoqXwAbggS1x6Cfhv4lyQdlfQVlRCWpWzNbHHJUvWXuxkgR755CTdUrWcPPK899PM6BXFa0bfMaar95nxRqiSsqakWqvy5klxzGStSq6r-umD-qh4kfOGUlbrij4vjgTjUiolj4s_a-xh6GIg0ZPF1_XnJYl7TCX-2iXMeW4MkfTxJ8lj2nd76EmCAUkXyHK1XhAIjiScHLkLWG6jGyccOgJjignIknzvAuRbfZsQ8kAsBIuJWOx70k-m_LJ45qHP-OruPSmuPn28Wp2Xl1_OLlaLy9KqRg5lzaC13HJWca9Ew7GpqXLOK-8oessrJWjdaABvHQftPcNKSOuYcFXllDgpLg5YF2FjdqnbQvptInTm9iOmawNp6GyPxlpwtJVWtl5LL6zWnDpoGNe8sdbbifXhwNqN7RadxTAk6B9BH3dC981cx72plOZKzsOc3gFS_DFiHsy2y_NJIGAcs-FcalGrupmlb_-TbuKYwnSpWSUkrSmlk4odVDbFnBP6-2EYNXNYzCEsZgqLmcNibibPm4db3Dv-pUP8BRO0vR8</recordid><startdate>20190618</startdate><enddate>20190618</enddate><creator>Huang, Di</creator><creator>Huang, Yu</creator><creator>Huang, Zisheng</creator><creator>Weng, Jiefeng</creator><creator>Zhang, Shuai</creator><creator>Gu, Weili</creator><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TM</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20190618</creationdate><title>Relation of AURKB over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines</title><author>Huang, Di ; Huang, Yu ; Huang, Zisheng ; Weng, Jiefeng ; Zhang, Shuai ; Gu, Weili</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c594t-71abc2c2162f5392e9705ddf5fd0efc26530798aafcd2a8ff1e634cd13d66d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Apoptosis</topic><topic>AURKB</topic><topic>Aurora B</topic><topic>Aurora B protein</topic><topic>Aurora kinase</topic><topic>BAX protein</topic><topic>Bcl-2 protein</topic><topic>BRCA</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Caspase</topic><topic>Caspase-3</topic><topic>Cell cycle</topic><topic>Cell lines</topic><topic>Cell proliferation</topic><topic>Cell viability</topic><topic>Chemical compounds</topic><topic>Enzyme inhibitors</topic><topic>ErbB-2 protein</topic><topic>Fibroblasts</topic><topic>Flow cytometry</topic><topic>Gelatinase B</topic><topic>Genes</topic><topic>Invasiveness</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>MicroRNAs</topic><topic>miRNA</topic><topic>Overexpression</topic><topic>Polymerase chain reaction</topic><topic>Polyploidy</topic><topic>Primary Research</topic><topic>Proteins</topic><topic>Reversine</topic><topic>Stem cells</topic><topic>Survival</topic><topic>Tissue inhibitor of metalloproteinase 1</topic><topic>Transforming growth factor-b1</topic><topic>Triple-negative breast cancer cells</topic><topic>Tumor cell lines</topic><topic>Viability</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Di</creatorcontrib><creatorcontrib>Huang, Yu</creatorcontrib><creatorcontrib>Huang, Zisheng</creatorcontrib><creatorcontrib>Weng, Jiefeng</creatorcontrib><creatorcontrib>Zhang, Shuai</creatorcontrib><creatorcontrib>Gu, Weili</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Cancer cell international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Di</au><au>Huang, Yu</au><au>Huang, Zisheng</au><au>Weng, Jiefeng</au><au>Zhang, Shuai</au><au>Gu, Weili</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relation of AURKB over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines</atitle><jtitle>Cancer cell international</jtitle><addtitle>Cancer Cell Int</addtitle><date>2019-06-18</date><risdate>2019</risdate><volume>19</volume><issue>1</issue><spage>166</spage><epage>166</epage><pages>166-166</pages><artnum>166</artnum><issn>1475-2867</issn><eissn>1475-2867</eissn><abstract>New therapeutic drug for breast cancer (BRCA), especially triple negative BRCA (TNBC), is urgently needed. Even though 2-(4-morpholinoanilino)-6-cyclohexylaminopurine (reversine) is an aurora kinase inhibitor, it also inhibits some cancer cells and human BRCA cells. However, the potential roles of reversine as a novel therapeutic agent for the treatment of BRCA remains unknown and must be further investigation. Thus, the relationship of reversine to aurora kinase in BCRA has not been reported. The relationship between AURKB and survival rate in BRCA has never been reported. Herein, we tested the roles of reversine on different BRCA cell line subtypes. We also investigated the relationship between AURKB and survival rate in BRCA as well as reversine to Aurora kinase expression in BCRA cell lines, including TNBC subtype, 4T1, MDA-MB-231, and luminal subtype MCF-7.
Cell viability and apoptosis were detected using Cell Counting Kit-8 and flow cytometry analysis, respectively. Apoptotic and tumor-related proteins were tested using Western blot analysis. Important microRNAs that regulate BRCA were analyzed using RT-PCR. UALCAN public databases were used to analyze the targeted gene profiles, and the PROGgeneV2 database was used to study the prognostic implications of genes.
Reversine inhibits cell proliferation and induces cell apoptosis by modulating caspase-3 and bax/bcl-2 among the three cell lines. Data from the UALCAN public database show that BRCA tissues expressed high gene levels of
, and
compared with the normal tissue. Among the over-expressed genes in BRCA,
ranks 9th in TNBC, 49th in luminal subtype, and 48th in HER2 subtype. High
level in BRCA is highly related to the low survival rate in patients displayed in 18 databases searched via PROGgeneV2. The protein levels of aurora B kinase (Aurora B), which is encoded by
gene, are highly suppressed by reversine in the three cell lines. The tumor-related proteins TGF-β1, TIMP1, and MMP9 are partially suppressed by reversine but with different sensitivity in the three cell lines. The reversine-affected microRNAs, such as miR129-5p, miR-199a-3p, and miR-3960, in MDA-MB-231 cell line might be the research targets in TNBC regulation.
In BRCA, the level of
are over-expressed and is related to low survival rate. Reversine contributes to anti-growth effect in BRCA cell lines, especially for TNBC, by modulating the aurora B. However, the invasiveness, metastasis, and anti-tumor effects of reversine in vivo and in vitro must be further investigated.</abstract><cop>England</cop><pub>BioMed Central</pub><pmid>31244554</pmid><doi>10.1186/s12935-019-0885-z</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1475-2867 |
ispartof | Cancer cell international, 2019-06, Vol.19 (1), p.166-166, Article 166 |
issn | 1475-2867 1475-2867 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_ccad0b4c4bf84f3c8820da912829ccfc |
source | PubMed (Medline); Publicly Available Content (ProQuest) |
subjects | Apoptosis AURKB Aurora B Aurora B protein Aurora kinase BAX protein Bcl-2 protein BRCA Breast cancer Cancer therapies Caspase Caspase-3 Cell cycle Cell lines Cell proliferation Cell viability Chemical compounds Enzyme inhibitors ErbB-2 protein Fibroblasts Flow cytometry Gelatinase B Genes Invasiveness Kinases Medical prognosis Metastases MicroRNAs miRNA Overexpression Polymerase chain reaction Polyploidy Primary Research Proteins Reversine Stem cells Survival Tissue inhibitor of metalloproteinase 1 Transforming growth factor-b1 Triple-negative breast cancer cells Tumor cell lines Viability |
title | Relation of AURKB over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T21%3A35%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relation%20of%20AURKB%20over-expression%20to%20low%20survival%20rate%20in%20BCRA%20and%20reversine-modulated%20aurora%20B%20kinase%20in%20breast%20cancer%20cell%20lines&rft.jtitle=Cancer%20cell%20international&rft.au=Huang,%20Di&rft.date=2019-06-18&rft.volume=19&rft.issue=1&rft.spage=166&rft.epage=166&rft.pages=166-166&rft.artnum=166&rft.issn=1475-2867&rft.eissn=1475-2867&rft_id=info:doi/10.1186/s12935-019-0885-z&rft_dat=%3Cproquest_doaj_%3E2243407000%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c594t-71abc2c2162f5392e9705ddf5fd0efc26530798aafcd2a8ff1e634cd13d66d53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2243407000&rft_id=info:pmid/31244554&rfr_iscdi=true |